Clinical Trial Update: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD [Phase 2]

View source ↗

Summary

Phase 2 trial updates consolidation Brentuximab Vedotin in stage I/II Hodgkin lymphoma with PET positivity after 2 cycles of ABVD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED